Peptide Therapy NYC: FDA Status, Trials and How Access Works

12 min readWritten by Protocol Health Editorial TeamMedically reviewed by Richard Dentico, MDPublished Updated

Peptide therapy in NYC runs through a licensed prescriber and a compounding pharmacy, because the peptides New York clinics use are not FDA-approved drugs. The FDA places ipamorelin acetate in Category 2 under its 503B interim policy, the tier for bulk substances that may present significant safety risks, and BPC-157, CJC-1295, GHK-Cu, MOTS-c, selank and TB-500 were previously in Category 2 until their nominators withdrew them. Mechanism is well described for most of them; human outcome data is thin. Protocol Health prescribes peptides in person in Scarsdale, NY and by video across New York State.

Peptide Therapy NYC: FDA Status, Trials and How Access Works
Here’s what we’ll cover

Key takeaways

  • Peptide therapy in NYC is prescription-only. The peptides involved are compounded drugs, and none in this guide is FDA-approved for the uses clinics market (FDA, bulk drug substances with significant safety risks).
  • Several popular peptides carry FDA safety flags. The FDA places substances that may present significant safety risks in Category 2 under its interim policies (FDA).
  • Human outcome data are thin. A 2025 review found only three human pilot studies of BPC-157 and called it investigational (McGuire et al., 2025).
  • Mechanism is not outcome. Sermorelin's review base sits mainly in children with growth hormone deficiency, not healthy adults (Prakash and Goa, BioDrugs 1999).

What It Involves

How Does Peptide Therapy in NYC Work?

Peptide therapy in NYC is a prescription process, not a menu item. A licensed prescriber evaluates you, orders labs, writes for a specific peptide, and a compounding pharmacy prepares it. Most preparations are injected under the skin at home. Nothing in this category is sold over the counter in New York.

A peptide is a short chain of amino acids that acts as a signalling molecule. Sermorelin is the clearest example: it is a 29-amino-acid analogue of human growth hormone-releasing hormone, and a review of sermorelin in BioDrugs describes it as the shortest synthetic peptide with the full biological activity of GHRH, stimulating growth hormone secretion from the anterior pituitary. The peptide does not replace a hormone. It signals the pituitary to release more of your own.

The peptide clinic NYC market splits into two kinds of practice, and the difference shows up in the intake:

  • Med-spa add-on menus. Peptides sit alongside facials, cold plunge and IV drips. The visit is short, labs are often optional, and the peptide is sold as a package of sessions.
  • Physician-run practices. Peptides sit inside a longevity or hormone practice. Baseline bloodwork comes first, the prescriber documents why a specific peptide fits the finding, and follow-up labs decide whether it continues.

Both are legal. Only the second produces a record another clinician can read later. Protocol Health's peptide therapy program runs the second way: consultation, baseline labs, a prescription written against the labs, and follow-up set by your clinician. For how the main peptides work, see the peptide therapy guide.

FDA Status

The FDA List Most NYC Peptide Clinics Leave Out

The FDA list most NYC peptide clinics leave out is its public record of bulk substances nominated for compounding, and no compounded peptide in the table below has FDA approval for any use. The FDA keeps public lists of bulk drug substances nominated for compounding under sections 503A and 503B, and most popular peptides sit in Category 2 or among the withdrawn nominations.

The FDA states that bulk drug substances "that may present significant safety risks have been placed in category 2 under the interim policies." A second group was previously in Category 2 and was withdrawn by the nominators, and the FDA still publishes the safety risks it identified for each. Here is where the peptides New Yorkers ask about actually sit, per the FDA's own page on these substances:

PeptideFDA list positionFDA's stated concern
Ipamorelin acetate503B Category 2; nomination withdrawnCompounded drugs "may pose risk for immunogenicity for certain routes of administration due to the potential for aggregation or peptide-related impurities"
GHRP-2, GHRP-6, ibutamoren mesylateCategory 2 (GHRP-2, GHRP-6: 503B; ibutamoren: 503A and 503B)Immunogenicity risk for GHRP-2 and GHRP-6; for ibutamoren mesylate, "the potential for congestive heart failure in certain patients"
CJC-1295Previously in Category 2; withdrawn by the nominatorsImmunogenicity risk plus "complexities with regard to ... peptide-related impurities and API characterization"; FDA also cites "serious adverse events associated with CJC-1295 including increased heart rate and systemic vasodilatory reaction"
BPC-157Previously in Category 2; withdrawn by the nominatorsImmunogenicity risk; "the agency lacks sufficient information to know whether the drug would cause harm when administered to humans"
GHK-Cu (injectable), MOTS-c, selank acetate, semax, TB-500, AOD-9604, epitalonPreviously in Category 2; withdrawn by the nominatorsFDA cites immunogenicity risk and limited or no human safety data
Where common peptides sit on the FDA's 503A/503B interim-policy lists, with the agency's own wording.

Protocol Health prescribes several of the peptides in that table, including GHK-Cu, Selank and Semax, so we have a commercial interest in them and say so here; stating the FDA's position plainly matters more than hiding it. A listing of Category 2 or withdrawn does not mean a peptide is banned or that a pharmacy committed a crime by compounding it. It means the FDA has not cleared that bulk substance for compounding under its interim policies and has written down the safety risks it identified. Any clinic that sells you BPC-157 or ipamorelin without telling you that is withholding the single most useful fact about it.

Ask a prospective clinic where the peptide it recommends sits on those lists. The answer is public, and a practice that cannot produce it has not read the file on the drug it wants to sell you.

Human Evidence

Does Peptide Therapy Work? What Human Trials Found

Whether peptide therapy works has limited human trial evidence behind it: outcome data for the popular peptides is thin, and the honest version of that sentence is more specific than most clinic pages make it.

BPC-157

A 2025 narrative review in Current Reviews in Musculoskeletal Medicine assessed the breadth and quality of the BPC-157 literature. Its finding: BPC-157 has demonstrated regenerative properties across numerous animal models, acting through VEGFR2 and nitric oxide signalling to promote angiogenesis and fibroblast activity, but "human data are extremely limited." Only three pilot studies have examined BPC-157 in humans, covering intra-articular knee pain, interstitial cystitis and intravenous safety and pharmacokinetics. No adverse effects were reported in them, and the authors concluded that until well-designed clinical trials are conducted, BPC-157 should be considered investigational and approached with caution.

One of those pilots was a retrospective chart review of 17 knee-pain patients at a single clinic, with outcomes collected by phone survey and no validated scoring tool (Lee et al., 2021). Three pilot studies is not nothing. It is not a basis for promising a torn tendon will heal.

Sermorelin

The published review base for sermorelin sits in a different population than the one most NYC clinics market to. The BioDrugs review covers its use in diagnosing and treating children with idiopathic growth hormone deficiency, where intravenous sermorelin served as a relatively specific provocative test for growth hormone deficiency. Adults seeking better sleep and recovery are extrapolating from that work, not citing a trial in people like themselves. Sermorelin is prescribed in the United States as a compounded preparation. The approved product, Geref, was discontinued, so compounded sermorelin is an unapproved drug.

What this means for a decision

For a decision, this means mechanism and outcome are different claims. For most of these peptides the mechanism is well characterised and the outcome in healthy adults is not. Ipamorelin was described as a selective growth hormone secretagogue from cell, rat and swine experiments (Raun et al., 1998). GHK-Cu's case rests largely on laboratory and gene-expression data (Pickart and Margolina, 2018). Semax's placebo-controlled human data include a brain-imaging study in 24 healthy volunteers (Lebedeva et al., 2018). A prescriber who says so is giving you better information than one who quotes a transformation story. This article gives no doses; the prescribing clinician sets any dose against your labs and history. In short, the human trials found well-described mechanisms and very little outcome data.

Safety

Is Peptide Therapy Safe? Side Effects and Risks

Peptide therapy is not established as safe for the compounded peptides NYC clinics prescribe, because the FDA has flagged specific potential risks and the human safety data are small. Safe is a claim the evidence has not yet earned for most of them, and the honest answer is that the risk is unquantified, not zero.

The risks the FDA names are concrete. For several injectable peptides it cites immunogenicity risk from aggregation and peptide-related impurities, meaning the immune system may react to the product itself. For CJC-1295 it cites serious adverse events including increased heart rate and systemic vasodilatory reaction. For ipamorelin it notes a published study reporting serious adverse events including death when ipamorelin was given intravenously for gastric motility, and says it lacks enough information to know whether other injectable routes would cause harm. Those findings come from the FDA's own listing, not from a clinic's marketing, and they are the baseline any prescriber should walk you through. Side effects specific to one peptide are covered in our ipamorelin side effects guide.

Product quality is a second risk. A compounded preparation is not reviewed by the FDA for safety, effectiveness or quality before it is marketed (FDA compounding Q&A), so the pharmacy and the prescriber carry the quality burden. Online "research chemical" vials carry neither. The legal side of that line is in are peptides legal?.

In short, peptide therapy has documented risks, thin human safety data and no FDA approval for the compounded products involved, and a clinic that discusses all three before prescribing is doing its job.

Vetting a Clinic

How Do You Choose a Peptide Doctor in NYC?

Choosing a peptide doctor in NYC is mostly a documentation question. The clinics worth your money answer these without hesitating.

  • Is the prescriber licensed in New York? Required for any patient located in the state, in person or by video.
  • What labs do you run before prescribing, and what would make you decline? A clinic with no declining criteria is a retailer.
  • Which compounding pharmacy fills this, and is it licensed in New York? You are entitled to the name.
  • Where does this peptide sit on the FDA's 503A/503B interim-policy lists? The answer is public. A clinic that does not know it has not read it.
  • Does this drug have FDA approval for any use? For compounded peptides such as BPC-157 and CJC-1295, it does not.
  • What follow-up labs are scheduled, and who reads them?
  • What is the stopping rule? Treatment that only ever continues is a subscription, not care.

Bring the same questions to a med-spa and a physician practice. The gap between the two answers is the whole decision.

Across New York

Is Peptide Therapy Available on Long Island and in Westchester?

Peptide therapy beyond Manhattan, in Westchester, on Long Island and upstate, is available because a New York medical license covers the entire state, so peptide therapy in New York is not a five-borough question. Patients in Westchester, on Long Island and in the Hudson Valley, the Capital Region and the Southern Tier can be treated by any New York-licensed prescriber by video.

That matters because the physical supply is concentrated in Manhattan. Someone looking for peptide therapy on Long Island or in the Hudson Valley is handed a map built for a different borough.

Protocol Health sits in Scarsdale, in Westchester County, which puts in-person care inside a short drive for most of Westchester and a straight Metro-North ride from Grand Central. For everyone else in the state, the consultation and follow-up happen by video. Westchester readers have a dedicated page: peptide therapy near me in Westchester.

Our Approach

Peptide Therapy NYC at Protocol Health: Scarsdale and Statewide Telehealth

Protocol Health is a physician-led longevity practice in Scarsdale, NY, treating patients in person at its Scarsdale clinic and by telehealth in New York, New Jersey, Connecticut, Florida and California.

Care starts with a consultation and baseline labs. The treating clinician decides whether a peptide is appropriate, which one, and at what dose, against those labs and your history. Follow-up is set by your clinician. Protocol Health's peptide catalogue includes sermorelin, BPC-157, ipamorelin, CJC-1295, GHK-Cu, Selank, Semax and glutathione, alongside advanced lab testing.

The summary a New Yorker should carry into any consultation: peptide therapy in NYC is prescription-only, the peptides involved are compounded, unapproved drugs, several of them appear on the FDA's 503A/503B interim-policy lists for documented safety reasons, and the human evidence is mechanistic more often than it is outcome-based. A clinic that tells you all four is a clinic worth booking. Start with the two-minute health quiz or contact the Scarsdale office.

Bottom Line

The Bottom Line

Peptide therapy in New York is legal, prescription-only and thinly evidenced, so the clinic's documentation matters most.

  • A prescriber and a pharmacy are required. Grey-market research vials have neither.
  • FDA status is public. Ask where a peptide sits on the FDA's compounding lists before you start (FDA).
  • BPC-157 is investigational. Its human evidence is three pilot studies (McGuire et al., 2025).
  • Sermorelin's data come from a different population. The review base covers children with growth hormone deficiency (Prakash and Goa, BioDrugs 1999).
  • Labs come before a prescription. A physician-run practice decides against baseline bloodwork and sets a stopping rule.

FAQ

Frequently Asked Questions

Can you get peptides in NYC?

Yes, with a prescription from a clinician licensed in New York, filled by a licensed compounding pharmacy. Peptides are not sold over the counter in New York. Online vials labelled "research chemicals, not for human consumption" are not medicines and carry no pharmacy quality testing.

Are peptides legal in NY?

Peptides are legal in New York when prescribed by a New York-licensed clinician and compounded by a licensed pharmacy. Buying and self-injecting peptides without a prescription is not. Legality is separate from FDA status: compounded drugs are not FDA-approved, so the FDA does not verify their safety, effectiveness or quality before marketing (FDA compounding Q&A).

Is BPC-157 available in NYC?

BPC-157 is prescribed by some New York clinics as a compounded preparation, including Protocol Health. The FDA lists it among bulk substances previously in Category 2 and withdrawn by the nominators, citing immunogenicity risk and limited or no safety information. A 2025 review found only three pilot human studies and called it investigational.

Do I need labs before starting peptide therapy?

A physician-run practice orders baseline bloodwork before prescribing and repeat panels afterwards. Labs decide whether a peptide is appropriate, what dose fits, and when to stop. A clinic that prescribes with no bloodwork and no stopping rule is selling a product, not providing care.

Can I do peptide therapy by telehealth in New York?

Yes, when the prescriber holds a New York license, because the patient's location governs. That makes video care the practical route for Long Island, Westchester, the Hudson Valley and upstate New York. Protocol Health treats patients by telehealth in New York, New Jersey, Connecticut, Florida and California.

Which peptides does Protocol Health prescribe?

Protocol Health's catalogue includes sermorelin, BPC-157, ipamorelin, CJC-1295, GHK-Cu, Selank, Semax and glutathione, all compounded and none FDA-approved. Which one a patient receives, if any, is decided by the treating clinician against baseline labs and history.

Is peptide therapy safe?

Not established for the compounded peptides used in NYC clinics. The FDA lists immunogenicity risk for several injectable peptides, reports serious adverse events including increased heart rate with CJC-1295, and notes that BPC-157 has too little human safety information to judge harm (FDA). A physician-led practice screens with labs first and sets a stopping rule.

What is peptide therapy good for?

People seek it for recovery, sleep, body composition and skin, but none of the compounded peptides is FDA-approved for those uses. Human outcome data are limited: BPC-157 has three pilot human studies and is considered investigational (McGuire et al., 2025), and sermorelin's published review covers children with growth hormone deficiency (BioDrugs). Our peptide therapy guide covers each goal.

Explore

Related at Protocol Health

Book a peptide consultation

Medical disclaimer

This article is for education only and is not medical advice, diagnosis, or treatment. Talk to a licensed clinician before starting, stopping, or changing any medication.

Important safety information

References

  1. U.S. Food and Drug Administration. Certain bulk drug substances for use in compounding that may present significant safety risks. fda.gov. https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks
  2. McGuire FP et al., 2025. Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing. Curr Rev Musculoskelet Med. PMID 40789979. https://pubmed.ncbi.nlm.nih.gov/40789979/
  3. Prakash A et al., 1999. Sermorelin: a review of its use in the diagnosis and treatment of children with idiopathic growth hormone deficiency. BioDrugs. PMID 18031173. https://pubmed.ncbi.nlm.nih.gov/18031173/
  4. Lee E et al., 2021. Intra-Articular Injection of BPC 157 for Multiple Types of Knee Pain. Altern Ther Health Med. PMID 34324435. https://pubmed.ncbi.nlm.nih.gov/34324435/
  5. Raun K et al., 1998. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. PMID 9849822. https://pubmed.ncbi.nlm.nih.gov/9849822/
  6. Pickart L et al., 2018. Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data. Int J Mol Sci. PMID 29986520. https://pubmed.ncbi.nlm.nih.gov/29986520/
  7. Lebedeva IS et al., 2018. Effects of Semax on the Default Mode Network of the Brain. Bull Exp Biol Med. PMID 30225715. https://pubmed.ncbi.nlm.nih.gov/30225715/
  8. U.S. Food and Drug Administration. Compounding and the FDA: questions and answers. fda.gov. https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers

Why trust our physicians

Every article is reviewed by a licensed physician on our medical team and is kept current by our editorial team. Read our editorial policy and our medical review process.

Medically reviewed by
Richard Dentico, MD on
Written by
Protocol Health Editorial Team
First published
Last updated

See an error? Email care@protocolhealthmd.com and we will review it.

More on Peptide Therapy

All Peptides articles →